Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

Market Cap	14.26B -7.4%
Revenue (ttm)	9.36B -14.4%
Net Income	944.38M -12.9%
EPS	0.70 -12.9%
Shares Out	1.34B
PE Ratio	15.10
Forward PE	n/a
Dividend	0.30 (2.82%)
Ex-Dividend Date	Sep 16, 2025

Volume	4,314,200
Average Volume	9,688,973
Open	10.71
Previous Close	10.63
Day's Range	10.59 - 10.72
52-Week Range	9.69 - 11.80
Beta	0.33
RSI	50.96
Earnings Date	Mar 28, 2026

About SHA:600420

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 11,472
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600420

Financial Performance

In 2025, SHA:600420's revenue was 9.36 billion, a decrease of -14.40% compared to the previous year's 10.94 billion. Earnings were 944.38 million, a decrease of -12.85%.